Cotización Argen X - ARGX

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

588.20

Postura de Compra

586.00

Postura de Venta

596.00

Volume Operado de la Acción

38,969

587.40 Rango del Día 595.20

271.00 Rango de 52 semanas 595.20

Capitalización de Mercado [m]

34.818B

Precio Anterior

589.80

Precio de Apertura

589.00

Hora

588.2

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

63,051

Acciones en circulación

59,194,000

Rendimiento del Dividendo

Ratio Precio/Utilidad

-117.89

Beneficio por acción (BPA)

-4.98

turnover

1.27B

Beneficio neto

-295.05M

Sector

Coml Physical, Biologcl Resh

Industria

Coml Physical, Biologcl Resh

Sitio web

www.argenx.com

Sede

Amsterdam, North Holland, Nld

Fundado

Argen X SE is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker ARGX. The last closing price for Argen X was 589.80 €. Over the last year, Argen X shares have traded in a share price range of 271.00 € to 595.20 €.

Argen X currently has 59,194,000 shares in issue. The market capitalisation of Argen X is 34.91 € billion. Argen X has a price to earnings ratio (PE ratio) of -117.89.

argenx to Present at Upcoming Investor Conferences

November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for...

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx...

argenx to Participate at Upcoming Investor Conferences

November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference...

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability...

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced...

argenx to Present at Upcoming Investor Conferences

August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

$478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo following June 21st FDA approval On track to begin four additional registrational...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	5.4	0.926561427591	582.8	595.2	572.8	47687	584.8906621	DE
4	46.4	8.56404577335	541.8	595.2	527.8	69301	567.10772326	DE
12	90.9	18.278705007	497.3	595.2	456.3	63051	522.80520704	DE
26	248.2	73	340	595.2	338.4	62913	471.84515506	DE
52	171.9	41.2923372568	416.3	595.2	271	63311	414.14753379	DE
156	328.3	126.317814544	259.9	595.2	224.1	65668	371.7567332	DE
260	455.2	342.255639098	133	595.2	93.05	75518	293.74908472	DE

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
ALCYBCybergun	0.0002 € (100.00%)	10.06M
ALVETEGEIRO Pharma	0.124 € (58.97%)	481.8k
ALDVAlliance Developpement Capital Siic	0.074 € (32.14%)	6k
MLSRPSpeed Rabbit Pizza	8.20 € (30.16%)	19
MLSEQSequa Petroleum NV	0.011 € (29.41%)	12k
MLCOTCoretech 5	0.01 € (-41.18%)	200
ATOAtos SE	0.495 € (-32.65%)	17.92M
AFMEAffluent Medical	1.20 € (-21.05%)	21.92k
ALBIOBiosynex	2.095 € (-18.32%)	26.9k
TRACTTeract SA	1.03 € (-15.23%)	76.91k
BCPBanco Comercial Portugues SA	0.4457 € (2.20%)	44.64M
ALNEVNeovacs	0.0003 € (0.00%)	33.59M
ATOAtos SE	0.495 € (-32.65%)	17.92M
ALCYBCybergun	0.0002 € (100.00%)	10.06M
ORAOrange.	9.706 € (-2.99%)	9.65M